KROS

TentativeAI MemoPost-earnings T+3

Keros Therapeutics

As of 2026-08-17/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Rinvatercept Phase 2 DMD data • 2026-11-15

Base target: $13 / p=50% prob

Biggest risk

The Q2 loss of $1.45 per share missed third-party consensus, revenue was zero, and Keros has no marketed product. The initial post-release reaction was modestly positive, but the shares later weakened to $10.10 by August 14. Recent reported target reductions at BofA, Wells Fargo, and Leerink reinforce a cautious interpretation: [StockAnalysis historical prices](https://stockanalysis.com/stocks/kros/history/), [TipRanks KROS news](https://www.tipranks.com/stocks/kros).

Invalidation

Break below $8 or thesis failure.

What would change my mind?

The investment case rests on a long cash runway, lower operating spend, a Phase 2 DMD program with initial data expected in 2027, and Takeda advancing elritercept. The packet's $19.8333 median target implies substantial upside, but the target count is unavailable and should not be treated as a robust consensus.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-17

Base target

$13

p=50%

Bull target

$18

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 earnings digestion: runway offsets operating miss
Takeda-led elritercept Phase 3 execution
The investment case rests on a long cash runway, lower operating spend, a Phase 2 DMD program with initial data expected in 2027, and Takeda advancing elritercept.

BearKey bullets

Post-earnings price action showed weak follow-through, while reported analyst targets were reduced after the print.
Q2 EPS missed consensus and revenue was zero; Keros has no marketed product or recurring product revenue.
[#PR-EARNINGS-2026-08-04]

WatchKey bullets

Rinvatercept Phase 2 DMD data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $13 (p=50%)

Target spread vs base: +44% / -40%

Scenario probabilities

Bull Target: $18 (p=25%)Base Target: $13 (p=50%)Bear Target: $8 (p=25%)

Commentary

Primary-source earnings evidence supports a cautious monitoring view: the company has meaningful runway and pipeline milestones, but the Q2 print was a loss with zero revenue, and no robust analyst-revision, options, insider, or social dataset is available in the packet. The stock rose 1.38% immediately after the release but closed 1.5% below the August 4 close by August 14, indicating limited market confirmation. Direct DMD comparators are available, but their modalities and development stages differ materially, so peer evidence remains directional rather than valuation-grade.

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 earnings digestion: runway offsets operating miss
Takeda-led elritercept Phase 3 execution

Scenarios

Bull Target (Scenario probability)

$18 / p=25% prob

Base Target (Scenario probability)

$13 / p=50% prob

Bear Target (Scenario probability)

$8 / p=25% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-11-15
Rinvatercept Phase 2 DMD data
Keros initiated a Phase 2 rinvatercept study in Duchenne muscular dystrophy and continues to expect initial data in the first half of 2027. [#SEC-8K-2026-08-03]
Prob 65.00% • Move 35.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Q2 earnings digestion: runway offsets operating miss
2026-08-17
Q2 EPS missed consensus, revenue was zero, and the stock lacked durable post-print follow-through. Offsetting factors are lower R&D/G&A expense and $257.6 million of cash, which management said should fund operations into the first half of 2028. [#SEC-8K-2026-08-03]
Prob 55% • Move 5% • Priced-in 75%

Long-term Catalysts

Months to a year

Takeda-led elritercept Phase 3 execution
2027-08-17
Takeda plans to advance elritercept into a Phase 3 myelofibrosis anemia study, creating a partner-led development and milestone pathway, although timing and economics remain incompletely quantified. [#SEC-8K-2026-05-14]
Prob 50% • Move 20% • Priced-in 45%

Risks

Post-earnings price action showed weak follow-through, while reported analyst targets were reduced after the print.
Q2 EPS missed consensus and revenue was zero; Keros has no marketed product or recurring product revenue. [#PR-EARNINGS-2026-08-04]
Rinvatercept clinical outcomes are binary, with initial DMD data not expected until the first half of 2027.
Takeda's elritercept development path is positive but partner execution, regulatory outcomes, milestone timing, and economics remain uncertain.
The stated cash runway depends on current operating assumptions and does not eliminate longer-term financing or dilution risk.

Peers

Symbol	Summary
DTIL	Direct indication comparator: Precision BioSciences is advancing PBGENE-DMD in a Phase 1/2 Duchenne study, with initial data expected by year-end 2026. Its gene-editing modality and different stage make it an operating comparator, not a valuation benchmark. [Precision BioSciences IR](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-receives-us-fda-clearance-investigational/)
TRDA	Direct indication comparator: Entrada Therapeutics is advancing multiple Phase 1/2 exon-skipping programs for Duchenne muscular dystrophy. The modality, mutation-specific approach, and stage differ materially from rinvatercept, so the comparison is directional only. [Entrada Therapeutics IR](https://ir.entradatx.com/news-releases/news-release-details/independent-safety-data-monitoring-committee-recommends)
RGNX	Direct indication comparator: REGENXBIO has advanced RGX-202 through pivotal Duchenne development and reported positive topline Phase III results, making it substantially more advanced than Keros. It is useful for event context but not as a direct valuation peer. [REGENXBIO IR](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-positive-topline-results-pivotal-phase-iii/)

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

DTIL

Direct indication comparator: Precision BioSciences is advancing PBGENE-DMD in a Phase 1/2 Duchenne study, with initial data expected by year-end 2026. Its gene-editing modality and different stage make it an operating comparator, not a valuation benchmark. [Precision BioSciences IR](https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-receives-us-fda-clearance-investigational/)

TRDA

Direct indication comparator: Entrada Therapeutics is advancing multiple Phase 1/2 exon-skipping programs for Duchenne muscular dystrophy. The modality, mutation-specific approach, and stage differ materially from rinvatercept, so the comparison is directional only. [Entrada Therapeutics IR](https://ir.entradatx.com/news-releases/news-release-details/independent-safety-data-monitoring-committee-recommends)

RGNX

Direct indication comparator: REGENXBIO has advanced RGX-202 through pivotal Duchenne development and reported positive topline Phase III results, making it substantially more advanced than Keros. It is useful for event context but not as a direct valuation peer. [REGENXBIO IR](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-positive-topline-results-pivotal-phase-iii/)